Fig. 3: Maraviroc effects on the PSD proteome signature of AD + P.
From: Targeting the post-synaptic proteome has therapeutic potential for psychosis in Alzheimer Disease
Adult C57Bl/6 J WT mice were randomized to daily intraperitoneal injection of maraviroc 50 mg/kg or vehicle for 5 days. 1370 of the 1613 proteins that comprised our PSD signature of AD + P, including 201 of the 240 PSD proteins that were nominally significantly reduced in AD + P, were successfully quantified. a Maraviroc treatment had a net effect of increasing the abundance of 1370 proteins. The corresponding fold changes in AD + P vs AD-P for the identical proteins are also shown. b Maraviroc treatment similarly had a net effect of increasing abundance in the subset of 201 proteins. P values are from one sample t-tests where the null was a Log2(fold-change)=0.
